California health officials confirmed on Tuesday, Jan. 13, 2026, that a mutated influenza strain—widely described as a “super flu”—is circulating in the state as hospital admissions for influenza reached a season high. The California Department of Public Health (CDPH) said the variant is an H3N2 subclade K, a mutation of seasonal influenza A that has been detected globally. Authorities also reported a second pediatric death tied to this respiratory virus season, underscoring growing concern among clinicians and public-health officials. State leaders and infectious-disease experts urged vaccination, testing and timely treatment to limit severe outcomes.
Key Takeaways
- CDPH confirmed on Jan. 13, 2026, that a mutated H3N2 subclade K—termed the “super flu”—is present in California and has global detections.
- The state reported a second pediatric death attributed to seasonal influenza during the current respiratory season.
- About 15% of respiratory flu tests in California were positive as of Jan. 3, down from 17% through Dec. 27, 2025.
- Hospitalizations hit roughly 3.8 admissions per 100,000 residents in California as of Jan. 3, a season high.
- Experts say typical flu symptoms (fever, body aches, cough, headache) predominate, but subclade K may produce more severe malaise for some patients.
- Public-health officials emphasize that current seasonal vaccines still reduce severe illness and hospitalization despite antigenic differences.
Background
The influenza season in Northern Hemisphere winter typically rises after holiday travel and gatherings; clinicians often see increased case counts and hospital pressure in January. Subtypes of influenza A, including H3N2, frequently change through antigenic drift—small genetic shifts that can allow a strain to partially evade prior immunity. In recent months, genomic surveillance flagged a K subclade within H3N2 that has been reported in multiple countries, prompting close monitoring by state and federal public-health labs. California’s surveillance relies on laboratory testing networks, hospital reports and state-level genomic sequencing to track which strains are circulating and whether vaccine formulations retain effectiveness.
Vaccination campaigns began months earlier based on global strain predictions, but mismatches between circulating viruses and the vaccine can occur. Even in years with imperfect strain matching, clinical data historically show vaccines reduce the risk of severe disease, hospitalization and death. Antiviral treatments such as neuraminidase inhibitors and newer agents remain tools to treat high-risk patients and reduce complications when given promptly.
Main Event
On Jan. 13, 2026, CDPH issued a notice confirming detection of H3N2 subclade K in state surveillance samples and linking recent hospital activity to rising influenza circulation. The agency reported a second pediatric fatality for the season, though it did not provide patient-identifying details, consistent with privacy protocols. Laboratory positivity for influenza swabs climbed through December and, while the statewide percent positive declined slightly from late December into early January, hospital admissions continued to rise.
Clinicians in multiple California hospitals described busier emergency departments and an uptick in admissions for respiratory illness, particularly among older adults and young children. Testing capacity has been maintained through public and private labs, and clinicians are encouraged to test symptomatic patients, offer antivirals to high-risk individuals, and advise vaccination for those not yet immunized. Public messaging from CDPH highlighted vaccine availability and urged families to seek care promptly for worsening symptoms.
UC San Francisco infectious disease specialists noted that infected individuals generally present with typical influenza complaints—fever, cough, body aches and headache—but that some patients report feeling markedly worse than with routine seasonal flu strains. Health systems are monitoring intensive-care unit capacity and staffing as winter caseloads increase, and hospitals are coordinating with local health departments on surge plans where needed.
Analysis & Implications
The emergence of an H3N2 subclade with wider detection raises questions about vaccine match and the season’s clinical burden. H3N2 seasons historically drive more hospitalizations and deaths, especially among older adults and young children, because of both higher virulence and lower vaccine effectiveness compared with other subtypes. If subclade K differs antigenically from vaccine strains, population-level protection could be reduced, potentially increasing severe cases despite high vaccine uptake.
However, vaccine effectiveness is not binary. Even with antigenic drift, vaccination typically lessens disease severity and cuts the risk of hospitalization. Public-health benefit also depends on antiviral use, early testing, and clinical management across outpatient and inpatient settings. The state’s healthcare capacity and preparedness—stock of antivirals, ICU beds and staffing—will shape outcomes as cases evolve through winter.
On a broader scale, genomic surveillance and rapid data sharing are crucial. Detecting and characterizing subclade K allows vaccine strain committees, national authorities and vaccine manufacturers to assess whether mid-season adjustments or prioritized messaging are needed. International spread of this subclade underscores the interconnected nature of influenza surveillance and the importance of global sequencing efforts for early warning.
Comparison & Data
| Metric | Measure | Date |
|---|---|---|
| Percent positive flu tests (California) | 17% (through Dec. 27, 2025) | Dec. 27, 2025 |
| Percent positive flu tests (California) | ~15% (as of Jan. 3, 2026) | Jan. 3, 2026 |
| Hospital admissions (per 100,000) | ~3.8 admissions/100,000 (season high) | Jan. 3, 2026 |
The table above summarizes the recent laboratory positivity and hospitalization metrics released by state surveillance through early January. While percent positivity eased slightly between Dec. 27 and Jan. 3, hospitalization rates continued to climb, a pattern consistent with post-holiday transmission and incubation timing. These figures reflect aggregate state data and may mask regional variation across California counties.
Reactions & Quotes
“I think this particular strain makes people feel pretty horrible,” said Dr. Monica Gandhi, noting that symptoms are typical of influenza but that subclade K may not be fully covered by the current vaccine.
Dr. Monica Gandhi, UCSF (infectious-disease specialist)
Gandhi’s comment reflects clinicians’ observations of pronounced malaise in some patients and the concern that antigenic differences could blunt vaccine match in a subset of cases.
“Current seasonal flu vaccines remain effective at reducing severe illness and hospitalization, including the currently circulating viruses,” CDPH Director Dr. Erica Pan said, urging vaccination and noting that tests and treatments are widely available.
Dr. Erica Pan, CDPH (state public-health officer)
CDPH emphasized availability of vaccines and antiviral treatments and encouraged timely care-seeking, particularly for high-risk groups.
“Flu activity often peaks after holiday travel because of incubation and spread among gatherings,” public-health clinicians said, pointing to travel and family gatherings as likely contributors to the recent rise.
State and local health clinicians (collective comment)
Unconfirmed
- Whether subclade K causes higher intrinsic severity compared with prior H3N2 strains remains under study and is not definitively established.
- The extent to which current vaccines will reduce infection (versus just severe outcomes) against subclade K is still being evaluated by laboratory and field effectiveness studies.
- Reports of regional variation in case severity and spread patterns require further local surveillance to confirm trends across all California counties.
Bottom Line
California is confronting a winter influenza season in which a mutated H3N2 subclade K has been detected and hospitalizations reached about 3.8 admissions per 100,000 by Jan. 3, 2026. Although laboratory positivity eased slightly after late December, health systems are seeing increased hospital pressure and a concerning second pediatric death for the season.
Public-health officials continue to recommend vaccination, prompt testing for symptomatic individuals, and early antiviral treatment for those at higher risk. Continued genomic surveillance, timely clinical reporting and public adherence to vaccination and care guidance will determine how sharply this season’s burden evolves in the coming weeks.